


**WHAT IS CLAIMED IS:**

## 1. Compounds of Formula I:



5 wherein:

$R_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-O(CH_2)_nX$ ;

$n$  is an integer of 1-3;


$X$  is  $CONHR_6$  or  $CO_2R_6$ ;

10  $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

$R_3$ ,  $R_4$  and  $R_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$  or  $CO_2R_6$ ;

15  $R_6$ , and  $R_7$  are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof.

## 2. Compounds of Formula II:



20

wherein:

$R_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-O(CH_2)_nX$ ;

$n$  is an integer of 1-3;

X is  $\text{CONHR}_6$  or  $\text{CO}_2\text{R}_6$ ;

$\text{R}_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;


$\text{R}_3$ ,  $\text{R}_4$  and  $\text{R}_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{SO}_2\text{NHR}_6$ ,  $\text{NR}_6\text{R}_7$  or  $\text{CO}_2\text{R}_6$ ;

$\text{R}_6$ , and  $\text{R}_7$  are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $\text{R}_2$ ;

or a pharmaceutically acceptable salt thereof.

10

3. Compounds of Formula III:



wherein:

$\text{R}_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-\text{O}(\text{CH}_2)_n\text{CO}_2\text{R}_5$ ;

$n$  is an integer of 1-3;

$\text{R}_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

$\text{R}_3$ ,  $\text{R}_4$ , are each, independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{SO}_2\text{NHR}_5$ ,  $\text{NR}_5\text{R}_6$ , or  $\text{CO}_2\text{R}_5$ ;


$\text{R}_5$ ,  $\text{R}_6$  are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where aryl group is substituted with  $\text{R}_2$ ;

or a pharmaceutically acceptable salt thereof.

25

4. The compound of claim 1, which is 6-Methoxy-5-([4-(trifluoromethoxy)benzyl]amino)methyl)-2-naphthoic acid.

5. The compound of claim 1, which is 5-[[4-(4-Fluorobenzyl)amino]methyl]-6-methoxy-2-naphthoic acid.
6. The compound of claim 1, which is 5-([4-(Aminosulfonyl)benzyl]amino)methyl)-6-methoxy-2-naphthoic acid.
7. The compound of claim 1, which is 5-([4-(Dimethylamino)benzyl]amino)methyl)-6-methoxy-2-naphthoic acid.
8. The compound of claim 1, which is 6-(Carboxymethoxy)-5-([4-(trifluoromethoxy)benzyl]amino)methyl)-2-naphthoic acid.
9. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises administering to said mammal, a therapeutically effective amount of a compound of Formula I:




wherein:

- $R_1$  is hydroxyl, alkoxy of 1-4 carbons or  $-O(CH_2)_nX$ ;
- $n$  is an integer of 1-3;
- $X$  is  $CONHR_6$ , or  $CO_2R_6$ ;
- $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons or acyl of 1-4 carbons;
- $R_3$ ,  $R_4$  and  $R_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$  or  $CO_2R_6$ ;

$R_6$ , and  $R_7$  are each, independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof.

- 5 10. A method of treating or inhibiting type II diabetes in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of compound of Formula I:




wherein:

- $R_1$  is hydroxyl, alkoxy of 1-4 carbons or  $-O(CH_2)_nX$ ;  
 10  $n$  is an integer of 1-3;  
 $X$  is  $CONHR_6$  or  $CO_2R_6$ ;  
 $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;  
 15  $R_3$ ,  $R_4$  and  $R_5$  are each, independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$  or  $CO_2R_6$ ;  
 $R_6$ , and  $R_7$  are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
 or a pharmaceutically acceptable salt thereof.

20

11. A method of modulating glucose levels in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I:



wherein:

$R_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-O(CH_2)_nX$ ;

$n$  is an integer of 1-3;


$X$  is  $CONHR_6$  or  $CO_2R_6$ ;

5  $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons or acyl of 1-4 carbons;

$R_3$ ,  $R_4$  and  $R_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$  or  $rCO_2R_6$ ;

10  $R_6$ , and  $R_7$  are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition which comprises a compound of Formula I:



15

wherein:

$R_1$  is hydroxyl, alkoxy of 1-4 carbons, or  $-O(CH_2)_nX$ ;

$n$  is an integer of 1-3;

$X$  is  $CONHR_6$ , or  $CO_2R_6$ ;

20  $R_2$  is hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, or acyl of 1-4 carbons;

$R_3$ ,  $R_4$ , and  $R_5$  are each independently, hydrogen, halogen, hydroxyl, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, acyl of 1-4 carbons,  $CF_3$ ,  $OCF_3$ ,  $SO_2NHR_6$ ,  $NR_6R_7$ , or  $CO_2R_6$ ;

25  $R_6$ , and  $R_7$  are each independently, hydrogen, alkyl of 1-4 carbons, or alkylaryl where the aryl group is substituted with  $R_2$ ;  
or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.